Baker Bros. Advisors’ Latest Moves Involve ACADIA Pharmaceuticals Inc. (ACAD) & Synageva Biopharma Corp (TRMS)

Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Synageva Biopharma Corp (NASDAQ:TRMS). According to a filing with the SEC, Baker Bros. Advisors now owns 20.48 million shares of ACADIA Pharmaceuticals, versus 19.96 million shares held at the end of the fourth quarter. The current stake amasses 21.0% of the ACADIA’s common stock.

The stake has been upped under a public offering of common stock, the fund purchasing around 526,300 shares. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) conducted a public offering of 6.4 million shares  at a price of $28.50 per share. A 30-day option to purchase up to 960,000 shares of common stock of ACADIA has also been granted to the underwriters. The net proceeds from the offering, which are expected to amount to $182.4 million will be used to fund ongoing and new clinical trials, in the development and commercialization efforts for pimavanserin, for its other product candidates and for general corporate purposes.

Baker Bros. also revealed holding warrants for acquisition of common stock of ACADIA, which if exercised, will result in an aggregate of almost 2.0 million shares.

 

ACADIA Pharmaceuticals Inc. (ACAD)

Dr. Stephen R. Biggar an employee of Baker Bros. serves on the Board of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Mr. Biggar holds 12,500 options to purchase common stock of ACADIA Pharmaceuticals at a price of $17.01 per share expiring June 7, 2023. Stephen Biggar might also get additional securities as compensation for his service on the Board.

Of all the hedge funds we track, Baker Bros. Advisors is the largest shareholder of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Peter Kolchinsky’s  Ra Capital Management, is also long ACADIA and holds 1.17 million shares, with a reported value of $29.24 million.

In a separate filing Baker Bros. Advisors revealed that it purchased 375,000 shares of Synageva Biopharma Corp (NASDAQ:TRMS) at a price of $105.75 per share and now holds around 8.2 million shares.

Synageva Biopharma Corp (NASDAQ:TRMS) has also recently announced a public offering of  2.0 million shares at a price of $105.75 per share. Morever, the company has granted a 30-day option to the underwriters to purchase an additional 300,000 shares of common stock.

Baker Bros. focuses on biotechnology companies. A couple of months ago, Baker Bros. Advisors trimmed its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,500 shares, from 1,130,317 shares held earlier. Earlier in January, Baker Bros. also revealed owning 13.84 million shares of Genomic Health, Inc. (NASDAQ:GHDX), of which it received 4,100 shares against director retainer fees of $10,000

Baker Bros. Advisors has 12.99% of its equity portfolio invested in Pharmacyclics, Inc. (NASDAQ:PCYC) a clinical-stage biopharmaceutical company, the stake amassing 8.72 million shares worth $922.32 million. The second largest holding of Baker Bros. is Seattle Genetics, Inc. (NASDAQ:SGEN), a company that focuses on the development and commercialization of monoclonal antibody-based therapies for cancer, in which the fund owns around 20.7 million shares.

Disclosure: none

Recommended Reading:

Hound Partners & Arrow Capital Management Are Buying the Same Stocks

Sandell Asset Management Increases Holding of Bob Evans Farms Inc (BOBE) Shares

Steven Cohen’s SAC Capital Ups Passive Stake in Gogo Inc (GOGO)

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!